

Cancer-Related Fatigue and Sleep Disorders

JOSEPH A. ROSCOE,^a MARALYN E. KAUFMAN,^a SARA E. MATTESON-RUSBY,^b OXANA G. PALESH,^{a,d}
JULIE L. RYAN,^{a,c} SADHNA KOHLI,^a MICHAEL L. PERLIS,^b GARY R. MORROW^{a,b}

^aDepartment of Radiation Oncology, ^bDepartment of Psychiatry,
^cDepartment of Dermatology, and ^dDepartment of Medicine, University of Rochester School
of Medicine and Dentistry, James P. Wilmot Cancer Center, Rochester, New York, USA

Key Words. Cancer • Fatigue • Sleep • Insomnia • Symptoms

ABSTRACT

Sleep disorders, such as difficulty falling asleep, problems maintaining sleep, poor sleep efficiency, early awakening, and excessive daytime sleepiness, are prevalent in patients with cancer. Such problems can become chronic in some patients, persisting for many months or years after completion of cancer therapy. For patients with cancer, sleep is potentially affected by a variety of factors, including the biochemical changes associated with the process of neoplastic growth and anticancer treatments, and symptoms that frequently accompany cancer, such as pain, fatigue, and depression.

Fatigue is highly prevalent and persistent in patients with cancer and cancer survivors. Although cancer-related fatigue and cancer-related sleep disorders are distinct, a strong interrelationship exists between these

symptoms, and a strong possibility exists that they may be reciprocally related. The majority of studies that have assessed both sleep and fatigue in patients with cancer provide evidence supporting a strong correlation between cancer-related fatigue and various sleep parameters, including poor sleep quality, disrupted initiation and maintenance of sleep, nighttime awakening, restless sleep, and excessive daytime sleepiness.

This paper reviews the data from these studies with a view toward suggesting further research that could advance our scientific understanding both of potential interrelationships between sleep disturbance and cancer-related fatigue and of clinical interventions to help with both fatigue and sleep disturbance. *The Oncologist* 2007;12(suppl 1):35–42

Disclosure of potential conflicts of interest is found at the end of this article.

INTRODUCTION

Fatigue and sleep disturbance are two of the most frequent side effects experienced by patients with cancer. Although sleep disruption is common in these patients, it has been a neglected problem. This is partly because it has been seen as a normal and transient reaction to cancer and cancer treatment, and partly because of the underreporting of sleep disturbances by patients [1–4].

Patients with cancer report insomnia, poor sleep quality, and short sleep duration. On testing, they are frequently found to have low sleep efficiency (the ratio of time asleep to total time in bed) [5]. Precipitating factors for insomnia in patients with cancer include the diagnosis of cancer, the type and stage of cancer, pain, side effects of treatment (e.g., nausea, vomiting, etc.), and/or the direct iatrogenic effects of treatment on sleep. Once

Correspondence: Joseph A. Roscoe, Ph.D., Behavioral Medicine Unit, University of Rochester Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, New York 14642, USA. Telephone: 585-275-9962; Fax: 585-461-5601; e-mail: Joseph_Roscoe@URMC.Rochester.edu
Received December 8, 2006; accepted for publication January 4, 2007. ©AlphaMed Press 1083-7159/2007/\$30.00/0 doi: 10.1634/theoncologist.12-S1-35

The Oncologist 2007;12(suppl 1):35–42 www.TheOncologist.com

it begins, insomnia is often self-perpetuating because of the natural tendency of patients to compensate for sleep loss by extending their sleep opportunity, for example, by napping, going to bed earlier, and getting out of bed later. Such behavioral changes are enacted by patients in order to try to “recover what has been lost,” but they lead to a mismatch between sleep opportunity and sleep ability and result in more frequent and longer awakenings. It may also be that the fatigue that occurs with cancer and/or anticancer therapy may, in and of itself, prompt patients to extend their sleep opportunity and thus it too becomes a contributing factor for ongoing insomnia [6].

The occurrence of insomnia in patients with cancer is frequent and is often severe enough to warrant medical intervention. Approximately 25%–50% of all prescriptions written for patients with cancer are for hypnotics [7,8]. Additionally, sleep disruptions can persist in cancer survivors for many years after diagnosis and completion of treatment, making it one of the most pervasive problems faced by patients with cancer [9,10].

Reports over the past 20–25 years have begun to shed light on the putative relationship between cancer-related sleep disorders and cancer-related fatigue (CRF). Cancer survivors often experience cancer-related sleep disorders and CRF simultaneously, although to date the interrelationships between these symptoms have not been completely defined [11–17]. While most of the studies in this area are correlative in nature, it is generally the case that sleep disturbance is: (a) positively correlated with fatigue, (b) more severe in fatigued than in nonfatigued patients, and (c) a significant predictor of fatigue (e.g., the studies reported in [11,18–20]). These findings are consistent with the concept that fatigue and insomnia are reciprocally related and suggest the possibility that treatment for one may impact the other.

This review of the current literature on sleep disruption and fatigue in patients with cancer outlines both correlative analyses and longitudinal studies that have used self-report and actigraphy measures to evaluate sleep disturbance.

EVALUATING THE ASSOCIATION BETWEEN CANCER-RELATED FATIGUE AND SLEEP

Symptom Clusters

CRF and cancer-related sleep disorders are increasingly reported as part of a cluster of three or more interrelated symptoms, including pain, depression, and loss of concentration and other cognitive functions [21–23], suggesting that CRF and cancer-related sleep disorders may share a common underlying etiology. A longitudinal study

of 93 patients undergoing chemotherapy revealed that a symptom cluster consisting of pain, fatigue, and sleep disturbance adversely and synergistically affected patient functional status (Karnofsky Performance Scale) [24]. In addition, the three symptoms were correlated with one another, albeit only to a small degree (fatigue to sleep insufficiency, $r = -0.13$; pain to sleep insufficiency, $r = -0.06$; pain to fatigue, $r = 0.22$). In another study of the same symptom cluster, Given and colleagues [25] showed that pain, fatigue, and insomnia were significant and independent predictors of reductions in patient functioning 8 weeks after diagnosis compared with 3 months prior to diagnosis. Most recently, an analysis of the results of questionnaire assessments of fatigue, pain, and sleep disturbances in 84 patients with multiple primary cancer diagnoses revealed that pain influenced fatigue, both directly and indirectly, via its effect on sleep [26]. Of the 20% variation in fatigue that was explained by pain in this population, 35% was mediated by sleep disturbances.

Evidence from Prospective Studies

The majority of studies that have prospectively assessed the relationship between fatigue and sleep in patients with cancer or cancer survivors reveal strong correlations between fatigue and various sleep parameters, including poor sleep quality, disturbed initiation and maintenance of sleep, lower perceived adequacy of sleep, insufficient sleep, sleep disturbance, nighttime awakening, and restless sleep (Table 1) [11,18–20,27–47]. While most studies have been conducted in patients with breast cancer undergoing chemotherapy, correlations between fatigue and sleep disorders have also been noted in patients undergoing radiotherapy and surgery, as well as in a variety of other cancer types (Table 1).

Evidence Using Patient-Reported Assessment of Fatigue and Sleep Disturbance

Most studies of insomnia have evaluated the condition using single-item assessments and have not taken into consideration the related symptoms of fatigue and excessive sleepiness. There is, however, one large-scale study that provides data on the various insomnia phenotypes (i.e., the type of insomnia complaint—whether early, middle, or late) [34]. In that study of 982 patients (mean age, 65 years) with six different types of cancer (breast, gastrointestinal, gynecologic, genitourinary, lung, and nonmelanoma skin cancer), a “sleep survey” questionnaire was used to evaluate the presence of various sleep problems (e.g., insomnia due to difficulty falling asleep, waking up several times a night, waking up for a long time, or waking up too early). The most prevalent problems reported by this patient sample were: fatigue (44%), insomnia (31%), and excessive sleepiness

Table 1. Studies investigating correlations between cancer-related fatigue (CRF) and cancer-related sleep disorders (CRSDs)

| Study reference | Population | Cancer type | Study timing | Variable(s) related to key findings | Methods and instruments | Key findings related to a correlation between CRF and CRSDs |
|------------------------------|---|--|--|--|--|--|
| Åhsberg and Fürst [27] | n = 81, male and female, aged >18 yrs | Cancer located within the trunk (i.e., thorax, abdomen, pelvis, or back) | During and up to 3 months after radiotherapy | Perceived fatigue | Swedish Occupational Fatigue Inventory scale, Category Ratio 10 Scale, and Karolinska Sleepiness Scale | Sleepiness was a significant predictor of perceived level of fatigue |
| Ancoli-Israel et al. [28] | n = 85, female, aged 34–79 yrs | Stage I–III breast cancer | Prior to chemotherapy | (a) Fatigue, (b) objective sleep quality, (c) subjective sleep quality, (d) circadian rhythm | (a) Multidimensional Fatigue Symptom Inventory – short form, (b) actigraphy, (c) Pittsburgh Sleep Quality Index, (d) actigraphy | Significant ($p < .0001$) correlations between subjective measures of sleep and fatigue; no significant correlations between reports of fatigue and objective sleep parameters or circadian rhythm variables |
| Anderson et al. [18] | n = 354, male and female, aged 18–88 yrs | Various | Not related to treatment | (a) Fatigue, (b) sleep disturbance | (a) Brief Fatigue Inventory, (b) Sleep Disturbance Scale | Sleep disturbance was a statistically significant ($p < .001$) predictor of fatigue |
| Andrykowski et al. [29] | n = 88, female, aged 35–76 yrs | Stage I–III A breast cancer | 3–60 months after primary cancer treatment (including surgery, radiotherapy, and chemotherapy) | (a) Fatigue, (b) sleep quality | (a) Chalder Fatigue Scale and Piper Fatigue Scale, (b) Pittsburgh Sleep Quality Index | There was a significant correlation between fatigue and sleep quality |
| Berger [30] | n = 72, female, aged 33–69 yrs | Stage I/II breast cancer | Four-day period following chemotherapy and at midcycle | (a) Fatigue, (b) activity and rest cycles | (a) Piper Fatigue Scale, (b) wrist actigraph | Fatigue and disrupted activity/sleep inversely related ($p < .05$) |
| Berger and Farr [31] | n = 72, female, aged 33–69 yrs | Stage I/II breast cancer | Four-day period following chemotherapy and at midcycle | (a) Fatigue, (b) circadian activity/rest indicators | (a) Piper Fatigue Scale, (b) wrist actigraph | Reduced daytime activity, increased daytime sleep, and increased nighttime awakenings were associated with increased fatigue |
| Berger and Higginbotham [32] | n = 14, female, aged 32–69 yrs | Stage I/II breast cancer | During chemotherapy and 2 months following final treatment | (a) Activity, (b) sleep, (c) symptom distress, (d) fatigue | (a) Wrist actigraph, (b) Morin Sleep Diary, (c) Symptom Experience Scale, (d) Piper Fatigue Scale | Low activity, disrupted sleep patterns, and increased symptom distress were all correlated with fatigue |
| Bower et al. [11] | n = 1,957, female, mean age 55 yrs | Stage 0–III breast cancer | Following treatment | (a) Fatigue, (b) sleep disturbance | (a) Energy fatigue subscale of the Medical Outcomes Study Short-Form (36-Item) Health Survey 1.0, (b) Medical Outcomes Study Sleep Scale | When present, fatigue was found to be strongly associated with sleep disturbance |
| Broeckel et al. [19] | n = 61, female, aged 29–75 yrs | Breast cancer | Mean of 471 days following chemotherapy | (a) Fatigue severity, (b) sleep quality | (a) The Fatigue Scale from the Profile of Mood States, (b) Pittsburgh Sleep Quality Index | Severe fatigue was significantly correlated with poorer sleep quality ($p < .05$) and sleeping during the day ($p < .001$) |
| Curran et al. [33] | n = 25, female, aged 28–63 yrs | Stage 0–III breast cancer | 6–30 months following chemotherapy and/or radiotherapy | (a) Diurnal pattern of fatigue, (b) sleep duration | (a) 10-point Likert scale with Ecological Momentary Assessment, (b) diary recording of sleep duration | While fatigue was experienced following treatment, it was not correlated with sleep duration |
| Davidson et al. [34] | n = 982, male and female, mean age 65 yrs | Various | 33% received therapy in previous 6 months | Various “sleep phenomena,” including excessive fatigue | Sleep survey questionnaire | Patients who reported being overly fatigued were 2.5 times more likely to have insomnia than others |
| Faithfull and Brada [35] | n = 19, male and female, aged 20–71 yrs | Brain tumor | Following treatment | (a) Fatigue, (b) drowsiness | (a) Daily diary of visual analog scale score, (b) daily diary of visual analog scale score | Fatigue was correlated with drowsiness ($p < .01$) |

(Continued)

Table 1 (Continued)

| Study reference | Population | Cancer type | Study timing | Variable(s) related to key findings | Methods and instruments | Key findings related to a correlation between CRF and CRSDs |
|--------------------------|---|------------------------------|---|--|--|--|
| Hwang et al. [36] | n = 180, male, aged 30–89 yrs | Various | During treatment | (a) Fatigue, (b) feeling drowsy | (a) Brief Fatigue Inventory, Functional Assessment of Cancer Therapy-Fatigue; (b) Memorial Symptom Assessment Scale (Short Form) | In patients with clinically significant fatigue, 71% reported feeling drowsy and 51% reported difficulty sleeping; feeling drowsy was found to be a significant ($p < .001$) independent predictor of clinically significant fatigue |
| Jacobsen et al. [37] | n = 54, female, aged 28–77 yrs | Stage I–III breast cancer | During chemotherapy | (a) Fatigue, (b) sleep problems | Memorial Symptom Assessment Scale | The more frequent occurrence of sleep problems was associated with significant increases in fatigue severity |
| Miaskowski and Lee [38] | n = 24, female, mean age 57 yrs | Bone metastasis | During radiotherapy | (a) Fatigue, (b) sleep disturbances | (a) Lee Fatigue Scale, (b) wrist actigraph | Improvement in morning fatigue compared with evening fatigue was significantly correlated with better sleep efficiency |
| Mormont et al. [39] | n = 20, male and female, aged 20–75 yrs | Metastatic colorectal cancer | During chronomodulated chemotherapy | (a) Quality of life, including fatigue; (b) rest-activity rhythm | (a) European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, (b) actigraphy | Fatigue was correlated with circadian rhythm disruptions ($p = .05$) |
| Okuyama et al. [40] | n = 134, female, aged 28–86 yrs | Stage 0–III breast cancer | 18–1,894 days following treatment (surgery, radiotherapy, or chemotherapy) | (a) Fatigue, (b) sleep | (a) Cancer Fatigue Scale, (b) ad hoc self-administered questionnaire with 5-point Likert scale | Insufficient sleep was found to be one of the main determinants of fatigue |
| Redeker et al. [20] | n = 263, male and female, aged 19–82 yrs | Various | During chemotherapy | (a) Fatigue, (b) insomnia | Symptom Distress Scale | A significant correlation was observed between insomnia and fatigue |
| Richardson and Ream [41] | n = 129, male and female, aged 26–82 yrs | Various | During chemotherapy | (a) Fatigue, (b) perceived cause of fatigue | (a) Visual analog scale, (b) interview | Sleep-wake patterns were reported as one of the perceived causes of fatigue |
| Roscoe et al. [42] | n = 78, female, aged 34–79 yrs | Breast cancer | During chemotherapy | (a) Fatigue, (b) circadian sleep rhythm | (a) Fatigue Symptom Checklist, Multidimensional Assessment of Fatigue, (b) actigraphy | Increased symptoms of fatigue correlated with disruption of the circadian rhythm |
| Sarna [43] | n = 69, female, mean age 61 yrs | Lung cancer | 43% receiving therapy | (a) Fatigue, (b) insomnia | Symptom Distress Scale | 31% of patients with serious fatigue also experienced insomnia |
| Savard et al. [44] | n = 327, male, aged 47–80 yrs | Prostate cancer | Within 10 years following surgery | (a) Fatigue, (b) sleep | (a) Multidimensional Fatigue Index, (b) Insomnia Severity Index | No association between fatigue and insomnia |
| Sela et al. [45] | n = 100, male and female, aged 21–86 yrs | Various | During pain and symptom control treatment | (a) Fatigue, (b) sleep | (a) Edmonton Symptom Assessment Scale, (b) self-reported sleep questionnaire | Difficulty falling asleep, difficulty staying asleep, sleeping fewer hours, and early awakening were all significantly correlated with fatigue |
| Servaes et al. [46] | n = 150, female, mean age 46 yrs | Breast cancer | 6–70 months following treatment (combination of surgery, radiotherapy, or chemotherapy) | (a) Complaints of fatigue, (b) sleep disturbance | (a) Daily Observed Fatigue Score of the Self-Observation List and Fatigue severity subscale of the Checklist Individual Strength questionnaire, (b) Groningen Sleep Quality Scale, Sleep/rest subscale of the Sickness Impact Profile, and Sleep subscale of the Symptom Checklist | Sleep disturbance was significantly greater in severely fatigued versus nonfatigued disease-free patients |
| Smets et al. [47] | n = 250, male and female, mean age 64 yrs | Various | During radiotherapy | (a) Fatigue, (b) sleep | (a) Multidimensional Fatigue Inventory, (b) Groningen Sleep Quality Scale | Both quality of sleep and hours of sleep were significantly associated with fatigue |

(28%). The authors noted that patients who reported being overly fatigued were 2.5 times more likely to have insomnia than others. Of the 300 patients reporting insomnia, 76% noted waking several times a night, 44% had difficulty falling asleep, 35% reported waking for a long time, and 33% woke up too early. The duration of insomnia was 6 months or longer in 75% of cases.

Many studies have indicated strong positive correlations between self-reported changes in sleep and the fatigue experienced by patients with cancer [5,19,37,40,41,48]. Correlations between fatigue and sleep problems are still evident in some patients with cancer more than a year after completion of their treatment [11,19]. Servaes and colleagues [46] examined the differences in a range of quality-of-life measures in disease-free breast cancer survivors at a mean of 29 months after completion of treatment. Women who were severely fatigued experienced significantly greater sleep disturbance than women with less fatigue.

Not all published data support a correlation between sleep disorders and CRF. In a study of the diurnal pattern of off-treatment fatigue in breast cancer survivors, survivors had significantly greater levels of fatigue than either age-matched women with benign breast problems or healthy controls [33]. Surprisingly, however, there were no significant group or time effects and no significant group–time interaction for fatigue and sleep duration. In addition, no difference in the diurnal pattern of fatigue among the three groups was found. Similarly, Savard and colleagues [44] found no relationship between insomnia and fatigue in men treated with radical prostatectomy for prostate cancer. The authors noted the uniqueness of this negative finding, and suggested that this lack of association between fatigue and insomnia may be a result of the high correlation between fatigue and other risk factors determined in this study (i.e., depression, anxiety, and pain).

Objective Measurement of Sleep Continuity

A number of studies have also found correlations between an objective measure of sleep continuity—i.e., actigraphy—and self-reported fatigue [30–32,39,42]. Actigraphy is a simple, noninvasive method of measuring levels of daytime and nighttime activity that can be used to accurately estimate the duration of both daytime and nighttime sleep. In addition, activity patterns over several consecutive days can be analyzed using autocorrelational techniques to examine sleep consistency and continuity over time [49,50]. The actigraph is a device approximately the size of a watch that is worn on the wrist and contains an accelerometer, a microprocessor, and retrievable memory. Activity counts are stored to memory, typically in 30–60-second epochs

for 24-hour intervals. These data provide diurnal activity counts, nocturnal activity counts, and the means by which to infer sleep continuity parameters, for example, time in bed (sleep period), time awake after sleep onset, total sleep time, and potentially, sleep latency.

Figure 1 shows representative actigraphy data from a patient undergoing treatment for cancer. The top graph shows activity measured over a 24-hour period following the second treatment cycle. The bottom graph is a 24-hour period after the fourth treatment cycle, 8 weeks later, when the patient reported increased fatigue. Each graph is an activity histogram with the y-axis representing frequency of activity and the x-axis representing 24 hours of measurement. As can be seen, the patient was in bed for much longer following the later treatment compared with the earlier one (>9 hours versus <6 hours). While it is unknown why patients tend to increase their sleep opportunity (time in bed) in this manner, this behavioral change can be expected to be insomniogenic [51]. In addition, the substantial increase in time in bed is likely to correspond to “shallower” sleep (more stage I sleep and/or less slow-wave sleep), as




Figure 1. Activity patterns during fatigue. Twenty-four-hour activity patterns measured by actigraphy in a patient with cancer undergoing treatment, showing activity following the second treatment (top), and the activity pattern 8 weeks later after the fourth treatment, when the patient reported increased fatigue (bottom).

measured by polysomnography. This phenomenon is evident in the actigraphic data in this example, which show a 50% increase in nocturnal activity in this patient.

Several studies have used actigraphy to demonstrate the relationship between sleep continuity and fatigue. For example, Mormont and colleagues [39] found a significant inverse relationship between rest–activity patterns and fatigue in patients with metastatic colorectal cancer prior to chemotherapy. Berger and colleagues conducted studies using wrist actigraphy to monitor rest–activity patterns in patients with breast cancer who were receiving chemotherapy [30–32]. Those studies showed that patients who were less active in the day and had more restless sleep experienced significantly more intense fatigue ($p < .05$), and that the strongest association was between the number of nighttime awakenings and the degree of fatigue. The relationship between fatigue and sleep disruption was maintained up to 2 months after completion of therapy [32]. Fatigue following radiotherapy also correlates with sleep disorders. For example, a study using wrist actigraphy and the Lee Fatigue Scale explored the relationship between sleep disturbances and fatigue in 24 patients receiving radiation therapy for bone metastasis [38]. The study found that the improvement noted in morning fatigue scores compared with evening fatigue scores was significantly correlated with better sleep efficiency ($r = 0.37$) and decreased number of awakenings ($r = 0.30$).

Our group has used actigraphy to assess the association between sleep and sleep–wake patterns and fatigue in 78 patients with breast cancer at their second and fourth on-study chemotherapy cycles [42]. Severity of fatigue was assessed using two standard subjective measures on the seventh day after each treatment. Patients also wore an actigraph for 72 hours starting 6 days after each treatment. Daily patterns of sleep and activity were compared across the 3-day period by autocorrelation analyses to calculate a “consistency of sleep–wake pattern” score for each patient. Comparisons after the second cycle indicated that the two paper-and-pencil measures of fatigue correlated well with the actigraphic measure of sleep–wake pattern stability (both $p < .05$). The two subjective measures of fatigue were not significantly related to total daily sleep. They were, however, associated with increased daytime napping (both $p < .05$). Changes in fatigue from the second to the fourth on-study treatment were also significantly correlated with concurrent changes in the consistency of the sleep–wake pattern (both $p < .05$). Thus, overall, more fatigue was reported by patients with less stable sleep–wake patterns who frequently napped.

Most recently, Ancoli-Israel and colleagues [28] reported that sleep disorders and fatigue were prevalent in patients with breast cancer prior to the start of chemother-

apy. However, while subjective measures of the two symptoms were significantly correlated, no significant correlation was found between subjective measures of fatigue and objective evaluation of sleep (by actigraphy).

Correlations with Daytime Symptoms of Sleep Disturbance

Correlations have also been noted between fatigue and daytime symptoms of sleep problems such as feeling drowsy, daytime sleepiness, and napping [11,27,31,36]. Åhsberg and Fürst [27] examined different aspects of perceived fatigue in patients undergoing radiotherapy and found correlations for lack of energy and sleepiness with fatigue (Fig. 2). Using a multidimensional model, Hwang and coworkers [36] showed a significant correlation between a parameter of sleep rarely reported—feeling drowsy—and CRF.

Cancer-Related Fatigue and Sleep Disorders

In general, the evidence supports a close association between CRF and sleep disorders. Several recent reviews [3,6,52–56] indicate that CRF and cancer-related sleep disorders are associated, and their prevalence and association depends on the timing of assessment (before diagnosis, before treatment, during treatment, and at various times after treatment). Following a review of the epidemiology of insomnia in patients with cancer, Savard and Morin [2] concluded that insomnia disorder added “an additional risk for experiencing intense and persistent fatigue after cancer treatment.” Other investigators have suggested that CRF and sleep disturbances should be considered as a clinical




Figure 2. Perceived fatigue in patients with cancer receiving radiotherapy. Intensity of fatigue was measured using a category ratio scale (CR10); “lack of energy” was evaluated using the Swedish Occupational Fatigue Inventory (SOFI); sleepiness was assessed using the SOFI and the Karolinska Sleepiness Scale (KSS).

Abbreviation: RT, radiotherapy.

Based on data from Åhsberg E, Fürst CJ. Dimensions of fatigue during radiotherapy—an application of the Swedish Occupational Fatigue Inventory (SOFI) on cancer patients. *Acta Oncol* 2001;40:37–43.

syndrome [57]. Most of the work done in this area does indicate that poor sleep is a major factor in CRF. Indeed, in a recent review, O'Donnell [56] purported that although the two conditions of CRF and insomnia are distinct, evidence in the literature suggests a strong interrelationship.

CONCLUSIONS

Sleep disorders are a common and often chronic problem for both patients with cancer and cancer survivors. Until recently, such symptoms have attracted little attention. Although CRF and sleep disturbances are distinct conditions, they are closely linked in terms of prevalence, often occurring as part of a multisymptom cluster. Further investigation is warranted in order to better understand the nature of sleep disturbances, the complex relationship they have with CRF, and their association with other symptoms commonly reported by patients with cancer, such as depression, pain, and anxiety. Current understanding of the possible link between CRF and sleep disturbances suggests that

interventions targeting disordered sleep and daytime sleepiness could provide promising potential treatments for CRF. Given the emerging data that suggest sleep disturbance is common in patients with cancer and that it may be both a cause of and caused by fatigue, it follows that targeted treatment of either symptom may positively affect the other.

ACKNOWLEDGMENTS

The authors gratefully acknowledge support provided by National Cancer Institute grants 1R25-CA102618-01A1 and 2U10 CA037420-20, and American Cancer Society grants RSG01071-01-PBP and MRSG-04-233-01-CPPB. Publication of this article was supported by a grant from Cephalon, Inc., Frazer, PA.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

G.R.M. has acted as a consultant for MGI Pharma and Cephalon.

REFERENCES

- 1 Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. *J Pain Symptom Manage* 1995;10:423–431.
- 2 Savard J, Morin CM. Insomnia in the context of cancer: A review of a neglected problem. *J Clin Oncol* 2001;19:895–908.
- 3 Savard J, Simard S, Blanchet J et al. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. *Sleep* 2001;24:583–590.
- 4 Silberfarb PM, Hauri PJ, Oxman TE et al. Insomnia in cancer patients. *Soc Sci Med* 1985;20:849–850.
- 5 Owen DC, Parker KP, McGuire DB. Comparison of subjective sleep quality in patients with cancer and healthy subjects. *Oncol Nurs Forum* 1999;26:1649–1651.
- 6 Theobald DE. Cancer pain, fatigue, distress, and insomnia in cancer patients. *Clin Cornerstone* 2004;6(suppl 1D):S15–S21.
- 7 Derogatis LR, Feldstein M, Morrow GR et al. A survey of psychotropic drug prescriptions in an oncology population. *Cancer* 1979;44:1919–1929.
- 8 Stiefel FC, Kornblith AB, Holland JC. Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period. *Cancer* 1990;65:1048–1053.
- 9 Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. *J Clin Oncol* 1995;13:2737–2744.
- 10 Lindley C, Vasa S, Sawyer WT et al. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. *J Clin Oncol* 1998;16:1380–1387.
- 11 Bower JE, Ganz PA, Desmond KA et al. Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. *J Clin Oncol* 2000;18:743–753.
- 12 Bower JE, Ganz PA, Aziz N et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. *Psychosom Med* 2002;64:604–611.
- 13 Bower JE, Ganz PA, Dickerson SS et al. Diurnal cortisol rhythm and fatigue in breast cancer survivors. *Psychoneuroendocrinology* 2005;30:92–100.
- 14 Hickok JT, Roscoe JA, Morrow GR et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. *Cancer* 2005;104:1772–1778.
- 15 Morrow GR, Tian L, Roscoe JA et al. The relationship between circadian rhythm and fatigue in breast cancer patients. *Proceedings of the Society of Behavioral Medicine's Twenty-First Annual Meeting* 2000;22 (suppl):S188.
- 16 Morrow GR, Andrews PL, Hickok JT et al. Fatigue associated with cancer and its treatment. *Support Care Cancer* 2002;10:389–398.
- 17 Morrow GR, Shelke AR, Roscoe JA et al. Management of cancer-related fatigue. *Cancer Invest* 2005;23:229–239.
- 18 Anderson KO, Getto CJ, Mendoza TR et al. Fatigue and sleep disturbance in patients with cancer, patients with clinical depression, and community-dwelling adults. *J Pain Symptom Manage* 2003;25:307–318.
- 19 Broeckel JA, Jacobsen PB, Horton J et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. *J Clin Oncol* 1998;16:1689–1696.
- 20 Redeker NS, Lev EL, Ruggiero J. Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. *Sch Inq Nurs Pract* 2000;14:275–290; discussion 291–298.
- 21 Armstrong TS, Cohen MZ, Eriksen LR et al. Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. *J Nurs Scholarsh* 2004;36:197–206.
- 22 Dodd MJ, Miaskowski C, Lee KA. Occurrence of symptom clusters. *J Natl Cancer Inst Monogr* 2004;(32):76–78.
- 23 Paice JA. Assessment of symptom clusters in people with cancer. *J Natl Cancer Inst Monogr* 2004;(32):98–102.
- 24 Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. *Oncol Nurs Forum* 2001;28:465–470.

- 25 Given B, Given C, Azzouz F et al. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. *Nurs Res* 2001;50:222–232.
- 26 Beck SL, Dudley WN, Barsevick A. Pain, sleep disturbance, and fatigue in patients with cancer: Using a mediation model to test a symptom cluster. *Oncol Nurs Forum* 2005;32:542.
- 27 Åhsberg E, Fürst CJ. Dimensions of fatigue during radiotherapy—an application of the Swedish Occupational Fatigue Inventory (SOFI) on cancer patients. *Acta Oncol* 2001;40:37–43.
- 28 Ancoli-Israel S, Liu L, Marler MR et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. *Support Care Cancer* 2006;14:201–209.
- 29 Andrykowski MA, Curran SL, Lightner R. Off-treatment fatigue in breast cancer survivors: A controlled comparison. *J Behav Med* 1998;21:1–18.
- 30 Berger AM. Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. *Oncol Nurs Forum* 1998;25:51–62.
- 31 Berger A, Farr L. The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. *Oncol Nurs Forum* 1999;26:1663–1671.
- 32 Berger AM, Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: A pilot study. *Oncol Nurs Forum* 2000;27:1443–1448.
- 33 Curran SL, Beacham AO, Andrykowski MA. Ecological momentary assessment of fatigue following breast cancer treatment. *J Behav Med* 2004;27:425–444.
- 34 Davidson JR, MacLean AW, Brundage MD et al. Sleep disturbance in cancer patients. *Soc Sci Med* 2002;54:1309–1321.
- 35 Faithfull S, Brada M. Somnolence syndrome in adults following cranial irradiation for primary brain tumours. *Clin Oncol (R Coll Radiol)* 1998;10:250–254.
- 36 Hwang SS, Chang VT, Rue M et al. Multidimensional independent predictors of cancer-related fatigue. *J Pain Symptom Manage* 2003;26:604–614.
- 37 Jacobsen PB, Hann DM, Azzarello LM et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates. *J Pain Symptom Manage* 1999;18:233–242.
- 38 Miaskowski C, Lee KA. Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: A pilot study. *J Pain Symptom Manage* 1999;17:320–332.
- 39 Mormont MC, Waterhouse J, Bleuzen P et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. *Clin Cancer Res* 2000;6:3038–3045.
- 40 Okuyama T, Akechi T, Kugaya A et al. Factors correlated with fatigue in disease-free breast cancer patients: Application of the Cancer Fatigue Scale. *Support Care Cancer* 2000;8:215–222.
- 41 Richardson A, Ream E. The experience of fatigue and other symptoms in patients receiving chemotherapy. *Eur J Cancer Care (Engl)* 1996;5(2 suppl):24–30.
- 42 Roscoe JA, Morrow GR, Hickok JT et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. *Support Care Cancer* 2002;10:329–336.
- 43 Sarna L. Correlates of symptom distress in women with lung cancer. *Cancer Pract* 1993;1:21–28.
- 44 Savard J, Simard S, Hervouet S et al. Insomnia in men treated with radical prostatectomy for prostate cancer. *Psychooncology* 2005;14:147–156.
- 45 Sela RA, Watanabe S, Nekolaichuk CL. Sleep disturbances in palliative cancer patients attending a pain and symptom control clinic. *Palliat Support Care* 2005;3:23–31.
- 46 Servaes P, Verhagen S, Bleijenbergh G. Determinants of chronic fatigue in disease-free breast cancer patients: A cross-sectional study. *Ann Oncol* 2002;13:589–598.
- 47 Smets EM, Visser MR, Willems-Groot AF et al. Fatigue and radiotherapy: (A) experience in patients undergoing treatment. *Br J Cancer* 1998;78:899–906.
- 48 Irvine DM, Vincent L, Graydon JE et al. Fatigue in women with breast cancer receiving radiation therapy. *Cancer Nurs* 1998;21:127–135.
- 49 Kripke DF, Mullaney DJ, Messin S et al. Wrist actigraphic measures of sleep and rhythms. *Electroencephalogr Clin Neurophysiol* 1978;44:674–676.
- 50 Taphoorn MJ, van Someren E, Snoek FJ et al. Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis. *J Neurol* 1993;240:446–448.
- 51 Perlis ML, Pigeon W, Smith MT. Etiology and pathophysiology of insomnia. In: Kryger MH, Roth T, Dement WC, eds. *Principles and Practice of Sleep Medicine*. Philadelphia: W.B. Saunders Co, 2005:714–725.
- 52 Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: A review. *Eur J Cancer Care (Engl)* 2001;10:245–255.
- 53 Davidson JR, Waisberg JL, Brundage MD et al. Nonpharmacologic group treatment of insomnia: A preliminary study with cancer survivors. *Psychooncology* 2001;10:389–397.
- 54 Foley D, Ancoli-Israel S, Britz P et al. Sleep disturbances and chronic disease in older adults: Results of the 2003 National Sleep Foundation Sleep in America Survey. *J Psychosom Res* 2004;56:497–502.
- 55 Lee K, Cho M, Miaskowski C et al. Impaired sleep and rhythms in persons with cancer. *Sleep Med Rev* 2004;8:199–212.
- 56 O'Donnell JF. Insomnia in cancer patients. *Clin Cornerstone* 2004;6(suppl 1D):S6–S14.
- 57 Barton-Burke M. Cancer-related fatigue and sleep disturbances. Further research on the prevalence of these two symptoms in long-term cancer survivors can inform education, policy, and clinical practice. *Am J Nurs* 2006;106(3 suppl):72–77.

Cancer-Related Fatigue and Sleep Disorders

Joseph A. Roscoe, Maralyn E. Kaufman, Sara E. Matteson-Rusby, Oxana G. Palesh,
Julie L. Ryan, Sadhna Kohli, Michael L. Perlis and Gary R. Morrow

Oncologist 2007;12;35-42

DOI: 10.1634/theoncologist.12-S1-35

This information is current as of November 21, 2009

**Updated Information
& Services**

including high-resolution figures, can be found at:
http://www.TheOncologist.com/cgi/content/full/12/suppl_1/35

 **AlphaMed Press**